• Immunic posted a Q2 net loss of USD 34.1 million, or USD 0.80 per share, versus a net loss of USD 26.8 million, or USD 2.03 per share, a year earlier.
• Operating expenses rose to USD 35.3 million, including USD 7.2 million of non-cash stock-based compensation.
• R&D expense increased to USD 25.9 million from USD 21.3 million, driven by higher personnel costs and drug-drug interaction studies supporting a potential NDA.
• G&A expense climbed to USD 9.4 million from USD 5.7 million on higher personnel, legal and consultancy, and pre-commercial marketing costs.
• Cash and cash equivalents totaled USD 155.1 million; Phase 3 ENSURE relapsing MS top-line data is expected by end-2026, with a planned U.S. NDA filing in mid-2027 if positive.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2380248_en) on August 11, 2026, and is solely responsible for the information contained therein.